fashion -WSS

fashion

author：entertainment 2025-10-01 23:31:14 - browse：4

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Editas, Vertex strike deal on CRISPR

hotspot

WSS

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Humana cuts profit projections as Medicare Advantage costs soar

Independent physicians launch a new lobbying group

Hospitals owned by private equity see complications spike 25%

In Spain, a hospital brews its own CAR

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

How one medical school became remarkably diverse

Carvykti CAR

In age of alternative facts, a scholarly course on calling out crap

Dewpoint Therapeutics lays off staff after losing partnerships

The high cost of giving birth even with insurance

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Supreme Court strikes down use of affirmative action

What STAT readers think about the FDA and patient advocacy

Trump demands the U.S. pay no more for drugs than other countries … again

Prior authorization will have to move faster under new Biden rule

entertainment

Research misconduct: Proposed new rules face resistance

Three trends to watch in biotech in 2024

SNAP should offer more nutrition education

FDA clears AI tool for detecting skin cancer

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

eGenesis tests gene

hotspot

leisure time

knowledge

hotspot